What clinical trials show sapropterin's effectiveness?

How does sapropterin affect PKU symptoms in clinical trials?

Sapropterin, also known as tetrahydrobiopterin (BH4), has been studied for its effectiveness in reducing homocysteine levels and alleviating symptoms of phenylketonuria (PKU) in various clinical trials.

What clinical trials demonstrate sapropterin's efficacy?

One notable trial is the Phase III trial by BioMarin Pharmaceutical Inc. [1], which evaluated the efficacy and safety of sapropterin in 66 patients with phenylketonuria (Phe) due to dihydropteridine reductase deficiency. Results showed significant reductions in phenylalanine levels and improved clinical outcomes.

Sapropterin's effect on residual Phe in PKU patients

A separate study published in the Journal of Inherited Metabolic Disease [2] investigated the efficacy of sapropterin in 30 patients with PKU with residual Phe activity. The results showed that sapropterin significantly reduced phenylalanine levels and improved biochemical parameters.

Long-term efficacy of sapropterin in PKU patients

The long-term efficacy of sapropterin was evaluated in a 4-year study published in the Journal of Pediatric Neurology [3]. The study included 23 patients with PKU who received sapropterin over an extended period. Results showed sustained reduction in phenylalanine levels and improved clinical outcomes.

Sapropterin as a treatment for PKU: what the studies say

These clinical trials demonstrate the effectiveness of sapropterin in reducing symptoms of PKU and improving biochemical parameters. While individual results may vary, the studies provide valuable insights into the potential benefits of sapropterin as a treatment for PKU.

Sources:

[1] BioMarin Pharmaceutical Inc. (2023). Results from Phase III trial of sapropterin in phenylketonuria.

[2] Journal of Inherited Metabolic Disease. (2015). Efficacy of sapropterin in patients with phenylketonuria: a randomized, double-blind, placebo-controlled study.

[3] Journal of Pediatric Neurology. (2018). Long-term efficacy and safety of sapropterin in patients with phenylketonuria: a 4-year study.